SCHEMBL3811201

SCHEMBL3811201

CNC(=O)Oc1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.76
KDR P35968 10/20 0.76
RAF1 P04049 5/20 0.76
RET P07949 3/20 0.76
RIPK2 O43353 2/20 0.76
ABCB11 O95342 2/20 0.76
ABL1 P00519 2/20 0.76
HTR1A P08908 2/20 0.76
PDGFRB P09619 2/20 0.76
ADORA3 P0DMS8 2/20 0.76
KIT P10721 2/20 0.76
FGFR1 P11362 2/20 0.76
PDGFRA P16234 2/20 0.76
FLT1 P17948 2/20 0.76
MAOA P21397 2/20 0.76
EPHA1 P21709 2/20 0.76
TBXA2R P21731 2/20 0.76
EPHA2 P29317 2/20 0.76
TTK P33981 2/20 0.76
EPHX2 P34913 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922660 0.91 RAF1 (0.73) BRAFKDRRAF1RETRIPK2
SCHEMBL5493056 0.90 BRAF (0.70) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL29351376 0.86 RAF1 (1.00) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL432230 0.86 RAF1 (1.00) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL29349808 0.86 RAF1 (1.00) BRAFKDRRAF1RETRIPK2
SCHEMBL14751390 0.86 KDR (0.77) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL2555101 0.85 RAF1 (0.98) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL29555444 0.85 RAF1 (0.98) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL29496390 0.85 RAF1 (0.98) BRAFKDRRAF1RETRIPK2
Regorafenib SCHEMBL2554008 0.85 RAF1 (0.98) BRAFKDRRAF1RETRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1793824-B1 NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER HEALTHCARE LLC (US) 2015-11-18 EP claimed
EP-2129376-B1 Treatment of cancers with acquired resistance to KIT inhibitors BAYER HEALTHCARE LLC (US) 2013-07-24 EP claimed
EP-2097381-B1 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE BAYER HEALTHCARE LLC (US) 2013-06-19 EP claimed
EP-1663978-B1 FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS BAYER PHARMACEUTICALS CORP (US) 2007-11-28 EP claimed
EP-2089363-A1 POLYMORPH II OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]N-METHYLPYRIDINE-2-CARBOXAMIDE Bayer Schering Pharma Aktiengesellschaft (DE) 2009-08-19 EP disclosed
EP-2081902-A1 POLYMORPH III OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE Bayer Schering Pharma Aktiengesellschaft (DE) 2009-07-29 EP disclosed